Sera Prognostics SERA
NASDAQ SERA
$2.10 +0.11 (+5.53%)
At close: Aug 20, 2026 · 4:00 PM EDT

Sera Prognostics (SERA) Liabilities and Shareholders Equity (2020 - 2026)

Sera Prognostics' (SERA) quarterly Liabilities and Shareholders Equity came in at $93.5 million in Q1 2026, down 20.85% YoY from $118.2 million in Q1 2025, and down 8.23% on a QoQ basis from $101.9 million in Q4 2025.

Sera Prognostics (SERA) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Sera Prognostics (SERA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $93.5 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 20.85% year-over-year to $93.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $415.4 million (up 17.15% YoY) and the FY2025 annual result came in at $101.9 million, up 40.45% from the prior year.
  • Liabilities and Shareholders Equity retreated to $93.5 million in Q1 2026, from $101.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $134.9 million in Q1 2022 to a low of $72.6 million in Q4 2024.
  • A 5-year average of $102.4 million and a median of $101.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slipped 24.16% — and 2025, when it soared 40.45%.
  • Tracing SERA's Liabilities and Shareholders Equity over 5 years: stood at $116.3 million in 2022, then retreated by 17.96% to $95.4 million in 2023, then retreated by 23.96% to $72.6 million in 2024, then surged by 40.45% to $101.9 million in 2025, then declined by 8.23% to $93.5 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $93.5 million (Q1 2026), $101.9 million (Q4 2025), and $108.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Abbott Laboratories 198.70 Bn 193.10 Bn 7.27 Bn 109.22 Bn
2 Stryker 125.85 Bn 122.37 Bn 4.50 Bn 47.93 Bn
3 Medtronic 118.44 Bn 109.22 Bn 6.41 Bn 93.03 Bn
4 Boston Scientific 72.64 Bn 72.10 Bn 3.85 Bn 45.22 Bn
5 Edwards Lifesciences 51.94 Bn 47.69 Bn 1.35 Bn 13.87 Bn
6 Dexcom 34.48 Bn 32.53 Bn 830.00 Mn 6.46 Bn
7 GE HealthCare Technologies 33.60 Bn 31.49 Bn 2.18 Bn 37.25 Bn
8 Koninklijke Philips 26.30 Bn 22.98 Bn 4.55 Bn 31.04 Bn
9 Steris 23.00 Bn 22.52 Bn 684.20 Mn 10.74 Bn
10 Sera Prognostics 103.48 Mn 103.48 Mn -20,000.00 86.74 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 86.74 Mn
Mar 31, 2026 93.54 Mn
Dec 31, 2025 101.93 Mn
Sep 30, 2025 108.13 Mn
Jun 30, 2025 111.83 Mn
Mar 31, 2025 118.18 Mn
Dec 31, 2024 72.58 Mn
Sep 30, 2024 79.00 Mn
Jun 30, 2024 84.86 Mn
Mar 31, 2024 89.89 Mn
Dec 31, 2023 95.44 Mn
Sep 30, 2023 90.06 Mn
Jun 30, 2023 96.68 Mn
Mar 31, 2023 105.61 Mn
Dec 31, 2022 116.33 Mn
Sep 30, 2022 116.56 Mn
Jun 30, 2022 125.06 Mn
Mar 31, 2022 134.87 Mn
Dec 31, 2021 147.03 Mn
Sep 30, 2021 153.69 Mn